Avantium has announced that it has appointed Oskar Slotboom as its Chief Commercial Officer. Oskar will be responsible for the commercialization and partnering of Avantium’s YXY technology and new development programs.
“With Oskar we further strengthen the leadership team of Avantium during a critical time where the company is transitioning to the commercialization phase of its YXY technology. He has a proven track record at developing and managing commercial partnerships, structuring commercial deals, and pursuing go-to-market strategies in an entrepreneurial environment. We look forward to his contribution to the successful growth of Avantium,” said Tom van Aken, CEO of Avantium.
Oskar previously held positions in McKinsey & Company as a management consultant and later on business development and commercial management in Crucell, before it was acquired by Johnson & Johnson. After the acquisition Oskar led Vaccines & Infectious Diseases business in Johnson & Johnson’s pharma joint venture Xian Janssen in Beijing, China. Oskar Slotboom has an MSc degree in Chemical Engineering of the University of Twente and holds a MBA from INSEAD.